Johnson & Johnson's earnings call revealed cautious guidance for 2009, projecting flat operational sales growth and modest EPS growth of 1% to 3%. The company faces headwinds from patent expirations on key pharmaceutical products and acknowledges the impact of the economic downturn on its consumer and medical device segments. Despite management's confidence, the subdued outlook and economic uncertainties are likely to result in short-term negative sentiment affecting the stock price.

[-1]